Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| LABCORP HOLDINGS INC.LH · Entity 1277 | CEO, Covance Drug Development | April 03, 2019 | April 05, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
LABCORP HOLDINGS INC.
Report date April 03, 2019 · Filed April 05, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 16,941 |
Ending reported balance
After 2019-04-03 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2019-04-03 · Exercise / conversion · Acquired 2,424 · Balance 18,025 F1: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Row 2 · 2019-04-03 · Tax withholding · Disposed 1,084 · Balance 16,941 F2: Stock withholding to satisfy tax withholding obligations. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 19,787 |
Reported balance
After 2019-04-03 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-04-03 · Exercise / conversion · Disposed 2,424 · Balance 19,787 F1: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3: The Restricted Stock Units vest in three installments as follows: 20% of the Restricted Stock Units vested on April 3, 2019; 30% of the Restricted Stock Units will vest on April 3, 2020; and 50% of the Restricted Stock Units will vest on April 3, 2021. F4: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. |
| Common StockSEC Table I · non-derivative | IndirectBy revocable trust | 40 |
Reported balance
Holding disclosure · report date 2019-04-03 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 40 |
| Common StockSEC Table I · non-derivative | IndirectBy irrevocable trust | 80 |
Reported balance
Holding disclosure · report date 2019-04-03 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 80 |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.
F2: Stock withholding to satisfy tax withholding obligations.
F3: The Restricted Stock Units vest in three installments as follows: 20% of the Restricted Stock Units vested on April 3, 2019; 30% of the Restricted Stock Units will vest on April 3, 2020; and 50% of the Restricted Stock Units will vest on April 3, 2021.
F4: This number reflects the aggregate number of Restricted Stock Units held by the reporting person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 03, 2019 Filed Apr 5, 2019 16:01 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionRestricted Stock Unit · Derivative | 2,424 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-014865 · form4.xml · derivative · entry 5 Ratliff John D · CIK 0001575951 · CEO, Covance Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,787 Underlying: Common Stock · 2,424 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units vest in three installments as follows: 20% of the Restricted Stock Units vested on April 3, 2019; 30% of the Restricted Stock Units will vest on April 3, 2020; and 50% of the Restricted Stock Units will vest on April 3, 2021. F3 · derivative.expiration_date: The Restricted Stock Units vest in three installments as follows: 20% of the Restricted Stock Units vested on April 3, 2019; 30% of the Restricted Stock Units will vest on April 3, 2020; and 50% of the Restricted Stock Units will vest on April 3, 2021. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| April 03, 2019 Filed Apr 5, 2019 16:01 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Tax withholdingCommon Stock | 1,084 | $156.68 | $169,841.12 |
DisclosureSEC source: 0001127602-19-014865 · form4.xml · nonDerivative · entry 2 Ratliff John D · CIK 0001575951 · CEO, Covance Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,941 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| April 03, 2019 Filed Apr 5, 2019 16:01 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionCommon Stock | 2,424 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-19-014865 · form4.xml · nonDerivative · entry 1 Ratliff John D · CIK 0001575951 · CEO, Covance Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,025 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 21:08 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | GrantNon-qualified Stock Options · Derivative | 21,800 | $0.00 Strike: $146.59 | $0.00 |
DisclosureSEC source: 0001127602-19-005984 · form4.xml · derivative · entry 7 Ratliff John D · CIK 0001575951 · CEO, Covance Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,800 Underlying: Common Stock · 21,800 shares Expires 2029-02-11 F7 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan. F8 · derivative.exercise_date: The option vests in three equal installments beginning on the date reflected in this column. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 21:08 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | GrantRestricted Stock Unit · Derivative | 5,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-005984 · form4.xml · derivative · entry 6 Ratliff John D · CIK 0001575951 · CEO, Covance Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,211 Underlying: Common Stock · 5,300 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F6 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on 2/12/2020. F6 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on 2/12/2020. F5 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 21:08 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionRestricted Stock Unit · Derivative | 1,463 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-005984 · form4.xml · derivative · entry 5 Ratliff John D · CIK 0001575951 · CEO, Covance Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,911 Underlying: Common Stock · 1,463 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F4 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on 2/12/19. F4 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on 2/12/19. F5 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 21:08 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Tax withholdingCommon Stock | 654 | $146.59 | $95,869.86 |
DisclosureSEC source: 0001127602-19-005984 · form4.xml · nonDerivative · entry 2 Ratliff John D · CIK 0001575951 · CEO, Covance Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,601 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 21:08 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionCommon Stock | 1,463 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-19-005984 · form4.xml · nonDerivative · entry 1 Ratliff John D · CIK 0001575951 · CEO, Covance Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,255 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 11, 2019 Filed Feb 13, 2019 16:55 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionRestricted Stock Unit · Derivative | 6,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-005556 · form4.xml · derivative · entry 5 Ratliff John D · CIK 0001575951 · CEO, Covance Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,374 Underlying: Common Stock · 6,100 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F4 · derivative.exercise_date: The Restricted Stock Units vested in three equal annual installments beginning on 2/9/17 and are now fully vested. F4 · derivative.expiration_date: The Restricted Stock Units vested in three equal annual installments beginning on 2/9/17 and are now fully vested. F5 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 11, 2019 Filed Feb 13, 2019 16:55 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Tax withholdingCommon Stock | 1,973 | $144.29 | $284,684.17 |
DisclosureSEC source: 0001127602-19-005556 · form4.xml · nonDerivative · entry 2 Ratliff John D · CIK 0001575951 · CEO, Covance Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,792 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 11, 2019 Filed Feb 13, 2019 16:55 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionCommon Stock | 6,100 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-19-005556 · form4.xml · nonDerivative · entry 1 Ratliff John D · CIK 0001575951 · CEO, Covance Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,765 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 07, 2019 Filed Feb 12, 2019 00:59 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionRestricted Stock Unit · Derivative | 1,863 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-005195 · form4.xml · derivative · entry 5 Ratliff John D · CIK 0001575951 · CEO, Covance Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,474 Underlying: Common Stock · 1,863 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F5 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on 2/7/18. F5 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on 2/7/18. F6 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 07, 2019 Filed Feb 12, 2019 00:59 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Tax withholdingCommon Stock | 556 | $147.46 | $81,987.76 |
DisclosureSEC source: 0001127602-19-005195 · form4.xml · nonDerivative · entry 2 Ratliff John D · CIK 0001575951 · CEO, Covance Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,665 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 07, 2019 Filed Feb 12, 2019 00:59 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionCommon Stock | 1,863 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-19-005195 · form4.xml · nonDerivative · entry 1 Ratliff John D · CIK 0001575951 · CEO, Covance Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,261 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| April 03, 2018 Filed Apr 5, 2018 14:14 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | GrantRestricted Stock Unit · Derivative | 12,120 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-014165 · form4.xml · derivative · entry 1 Ratliff John D · CIK 0001575951 · CEO, Covance Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,337 Underlying: Common Stock · 12,120 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units will vest in three installments as follows: 20% of the Restricted Stock Units will vest on April 3, 2019; 30% of the Restricted Stock Units will vest on April 3, 2020; and 50% of the Restricted Stock Units will vest on April 3, 2021. F2 · derivative.expiration_date: The Restricted Stock Units will vest in three installments as follows: 20% of the Restricted Stock Units will vest on April 3, 2019; 30% of the Restricted Stock Units will vest on April 3, 2020; and 50% of the Restricted Stock Units will vest on April 3, 2021. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 19:25 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | GrantRestricted Stock Unit · Derivative | 4,390 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-005993 · form4.xml · derivative · entry 2 Ratliff John D · CIK 0001575951 · CEO, Covance Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,217 Underlying: Common Stock · 4,390 shares Expires not disclosed F3 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F4 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on 2/12/19. F4 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on 2/12/19. F5 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 19:25 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | GrantNon-qualified Stock Options · Derivative | 17,100 | $0.00 Strike: $168.49 | $0.00 |
DisclosureSEC source: 0001127602-18-005993 · form4.xml · derivative · entry 1 Ratliff John D · CIK 0001575951 · CEO, Covance Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,100 Underlying: Common Stock · 17,100 shares Expires 2028-02-11 F1 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan. F2 · derivative.exercise_date: The option vests in three equal installments beginning on the date reflected in this column. Read SEC document |
| February 09, 2018 Filed Feb 13, 2018 19:08 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionRestricted Stock Unit · Derivative | 6,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-005415 · form4.xml · derivative · entry 5 Ratliff John D · CIK 0001575951 · CEO, Covance Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,827 Underlying: Common Stock · 6,100 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F4 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on 2/9/2017. F4 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on 2/9/2017. F5 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 09, 2018 Filed Feb 13, 2018 19:08 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Tax withholdingCommon Stock | 2,132 | $168.08 | $358,346.56 |
DisclosureSEC source: 0001127602-18-005415 · form4.xml · nonDerivative · entry 2 Ratliff John D · CIK 0001575951 · CEO, Covance Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,398 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 09, 2018 Filed Feb 13, 2018 19:08 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionCommon Stock | 6,100 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-18-005415 · form4.xml · nonDerivative · entry 1 Ratliff John D · CIK 0001575951 · CEO, Covance Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,530 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 07, 2018 Filed Feb 9, 2018 21:11 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionRestricted Stock Unit · Derivative | 1,863 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-004915 · form4.xml · derivative · entry 3 Ratliff John D · CIK 0001575951 · CEO, Covance Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,927 Underlying: Common Stock · 1,863 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on 2/7/18. F3 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on 2/7/18. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 07, 2018 Filed Feb 9, 2018 21:11 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Tax withholdingCommon Stock | 560 | $169.66 | $95,009.60 |
DisclosureSEC source: 0001127602-18-004915 · form4.xml · nonDerivative · entry 2 Ratliff John D · CIK 0001575951 · CEO, Covance Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,430 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 07, 2018 Filed Feb 9, 2018 21:11 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionCommon Stock | 1,863 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-18-004915 · form4.xml · nonDerivative · entry 1 Ratliff John D · CIK 0001575951 · CEO, Covance Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,990 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 09, 2017 Filed Feb 13, 2017 19:28 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionRestricted Stock Unit · Derivative | 6,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-005326 · form4.xml · derivative · entry 3 Ratliff John D · CIK 0001575951 · CEO, Covance Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,790 Underlying: Common Stock · 6,100 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on 2/9/17. F3 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on 2/9/17. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 09, 2017 Filed Feb 13, 2017 19:28 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Tax withholdingCommon Stock | 2,013 | $133.83 | $269,399.79 |
DisclosureSEC source: 0001127602-17-005326 · form4.xml · nonDerivative · entry 2 Ratliff John D · CIK 0001575951 · CEO, Covance Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,127 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 09, 2017 Filed Feb 13, 2017 19:28 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionCommon Stock | 6,100 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-17-005326 · form4.xml · nonDerivative · entry 1 Ratliff John D · CIK 0001575951 · CEO, Covance Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,140 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 07, 2017 Filed Feb 9, 2017 19:44 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | GrantNon-qualified Stock Options · Derivative | 21,300 | $0.00 Strike: $130.60 | $0.00 |
DisclosureSEC source: 0001127602-17-004733 · form4.xml · derivative · entry 2 Ratliff John D · CIK 0001575951 · CEO, Covance Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,300 Underlying: Common Stock · 21,300 shares Expires 2027-02-06 F4 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan. F5 · derivative.exercise_date: The option vests in three equal installments beginning on the date reflected in this column. Read SEC document |
| February 07, 2017 Filed Feb 9, 2017 19:44 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | GrantRestricted Stock Unit · Derivative | 5,590 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-004733 · form4.xml · derivative · entry 1 Ratliff John D · CIK 0001575951 · CEO, Covance Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,890 Underlying: Common Stock · 5,590 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on 2/7/18. F2 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on 2/7/18. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| October 03, 2016 Filed Oct 5, 2016 19:57 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | GrantRestricted Stock Unit · Derivative | 18,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-16-064300 · form4.xml · derivative · entry 1 Ratliff John D · CIK 0001575951 · CEO, Covance Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,300 Underlying: Common Stock · 18,300 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on 2/9/17. F2 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on 2/9/17. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.